| metastatic/advanced OC (mOC) - 1st line (L1) | |||
| metastatic/advanced OC (mOC) - 1st line (L1) | mOC - L1 - all population | mOC - L1 - PDL1 positive | |
| immune chekpoint inhibitors | |||
| anti-PD-(L)1 | |||
| atezolizumab based treatment | |||
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | AGO-OVAR 2.29/ENGOT-ov34 | ||
| atezolizumab plus SoC | IMagyn-050 ... | IMagyn-050 ... | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
